Digi International Introduces Digi IX30 Cellular Router Solution for Harsh Environments and Industry 4.0 Adoption
23.5.2022 16:00:00 EEST | Business Wire | Press release
Digi International (NASDAQ: DGII, www.digi.com), a leading global provider of Internet of Things (IoT) connectivity products and services, today unveiled Digi IX30, an industrial-hardened cellular router solution for harsh environments. Digi IX30 provides edge intelligence in a ruggedized, industry-leading design for the highest levels of reliability and flexibility. Coupled with Digi Remote Manager ®, Digi IX30 is an all-in-one solution for applications including distribution and automation, as well as remote machine and sensor monitoring in industries such as oil and gas production, water utilities, smart cities, and outdoor signage.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220523005021/en/
Digi's new IX30 cellular router solution for harsh environments and industry 4.0 adoption provides edge intelligence in a ruggedized, industry-leading design for the highest levels of reliability and flexibility. Coupled with Digi Remote Manager®, Digi IX30 is an all-in-one solution for applications including distribution and automation, as well as remote machine and sensor monitoring in industries such as oil and gas production, water utilities, smart cities, and outdoor signage. (Photo: Business Wire)
Digi IX30 is powered by Digi Remote Manager (Digi RM) and the Digi Accelerated Linux operating system (DAL OS). Digi RM is the command center of an intelligent network, enabling companies to efficiently configure, deploy, monitor, and manage tens of thousands of mission-critical devices and assets from a single desktop, tablet or smartphone. DAL OS, along with Digi RM, enables programmability for edge intelligence applications, interoperability for legacy serial devices/protocols, and MQTT Sparkplug B. These capabilities deliver critical connectivity between devices and sensors in the Industry 4.0 ecosystem, allowing users to experience high levels of security, control, and performance.
Ready for Public or Private Cellular Networks in ONE Solution
Digi IX30 delivers fast performance for public, private, and hybrid network deployments that support both licensed spectrum and CBRS Band 48 to enable migration between multiple networks in a single SKU. A future variant of Digi IX30 will include Anterix Band 8 along with Anterix Active certification to offer public and Anterix private cellular network support.
Battle Tested for Harsh Environments
Digi has designed its entire industrial (IX) product family to meet high-performance requirements in harsh environments with wide temperature ranges. Its Class 1, Division 2 (C1D2) and ATEX certifications makes it suitable for environments where potentially explosive gases, vapors, dust, or fibers may be present, and its DIN rail mounting design enables easy installation in field containers and cabinets.
Highest Density of I/O Options, Edge Intelligence and Complete Features for Global Deployments
Digi IX30 has the highest number of analog and digital I/O and serial ports along with rich protocol support and offers versatile integration options to manage a large of number of legacy systems from a single piece of equipment.
Digi IX30 was designed with dual Ethernet ports and GNSS, as well as support for remote sensors with four analog and four digital inputs and outputs. Leveraging its new Python programming implementation that provides interoperability with legacy serial devices/protocols, the Digi IX30 solution brings greater reliability, simplicity, and security to edge computing.
For customers who deploy and manage systems globally, Digi’s IX line provides a single SKU for high-volume global deployment, which simplifies inventory and reduces the costs of global distribution, deployment, and management.
“Digi IX30 – the newest member of our next-generation IX family of devices – builds on our widely successful legacy of industrial cellular routers,” said Sayeed Quazi, Sr. Principal Product Manager at Digi. “The ruggedized IX30, with additional compute for edge applications and additional analog and digital I/O, reduces the points of failure by eliminating the need for additional equipment. Its faster performance and LTE speeds deliver greater value through a complete, cost-effective IoT solution and significantly reduces OPEX in the most challenging deployment.”
The Digi IX30 industrial router is available immediately through global distributors.
About Digi International
Digi International (NASDAQ: DGII) is a leading global provider of IoT connectivity products, services, and solutions. It helps companies create next-generation connected products and deploy and manage critical communications infrastructures in demanding environments with high levels of security and reliability. Founded in 1985, Digi has helped customers connect more than 100 million things and counting. For more information, visit www.digi.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220523005021/en/
Contact information
Peter Ramsay
Global Results Communications
digi@globalresultspr.com
949.307.5908
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom